Israel’s Oramed (see here previously) has reported that its ORMD-0801 oral insulin candidate successfully reduced the liver fat in its Phase 2 trial on Type 2 diabetes patients with non-alcoholic steatohepatitis (“NASH”).  There were no safety issues in the double-blind, … Continue reading →

Israel’s Oramed (see here previously) has completed enrollment of patients for the Phase 3 trial of its oral insulin for the treatment of type 2 diabetes. Topline results of the trial are expected early 2023. https://www.prnewswire.com/news-releases/oramed-completes-patient-enrollment-in-pivotal-phase-3-oral-insulin-study-ora-d-013-1-301538222.html

Less than 6,400 Israelis now have the coronavirus, with just 178 serious cases. Also, an Israeli study shows Vitamin D deficient Covid-19 patients are 14 times more likely to be seriously or critically ill. Finally, Oramed’s oral vaccine has been … Continue reading →

Israel’s Oramed will shortly commence clinical trials of its Oravax vaccine – the world’s first oral Covid-19 vaccine (see here previously). Phase 1/2 trials will take place at Tel Aviv’s Sourasky (Ichilov) Medical Center with Phase 3 in countries desperate … Continue reading →

Israel’s Oramed (reported here previously) has launched Oravax – a joint venture with India’s Premas Biotech to develop a Covid-19 vaccine. The vaccine is administered orally (not injected) and targets 3 virus proteins, so should counter any mutations. Human trials … Continue reading →

Israel’s Oramed announced good results of its Phase 2b trials of ORMD-0801 treatment for Type 2 diabetes. Oramed will now discuss its Phase 3 plans with the US FDA. https://www.oramed.com/oramed-reports-positive-results-in-the-final-cohort-of-its-phase-2b-oral-insulin-trial/

Israeli TV news about the innovative treatment from Israel’s Oramed that will make life better for many of the 400 million people with diabetes. http://www.israelnationalnews.com/News/News.aspx/214498#.V3uKKjUbNf4

Israeli biotech Oramed has reported success in the Phase IIb study of its insulin capsule.  Oramed highlighted that it was the first time an oral solution showed a significant drop in blood sugar at night.  Oral insulin will replace injected … Continue reading →

Israel’s Oramed has signed a deal worth $50 million that gives China’s Hefei Life Science & Technology (HLST) the rights to Oramed’s oral insulin capsule ORMD-0801 in China, Hong Kong and Macau. ORMD-0801 will help treat the large and growing … Continue reading →